MX2022001434A - Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios. - Google Patents
Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.Info
- Publication number
- MX2022001434A MX2022001434A MX2022001434A MX2022001434A MX2022001434A MX 2022001434 A MX2022001434 A MX 2022001434A MX 2022001434 A MX2022001434 A MX 2022001434A MX 2022001434 A MX2022001434 A MX 2022001434A MX 2022001434 A MX2022001434 A MX 2022001434A
- Authority
- MX
- Mexico
- Prior art keywords
- malignant tumors
- immune checkpoint
- biomarker
- efficacy
- accessing
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title abstract 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title abstract 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title abstract 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title abstract 3
- 239000000090 biomarker Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
El problema a resolver por la presente invención es proporcionar un método para identificar a un paciente con tumor maligno que se puede esperar que se beneficie más de un inhibidor de punto de control inmunológico, y un agente para suprimir la progresión de, suprimir la recurrencia de, y/o tratar el tumor maligno, siendo prescrito en base a ello. La presente invención proporciona agentes para suprimir la progresión de, suprimir la recurrencia de, y/o tratar el tumor maligno, siendo prescritos en base a la identificación de un paciente con tumor maligno que se puede esperar que se beneficie más del inhibidor de punto de control inmune, en base a la combinación de dos conjuntos de elementos de evaluación y la condición específica definida por cada una de la combinación de los mismos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019144011 | 2019-08-05 | ||
JP2019216881 | 2019-11-29 | ||
PCT/JP2020/029882 WO2021025031A1 (ja) | 2019-08-05 | 2020-08-04 | 免疫チェックポイント阻害薬の有効性判定バイオマーカー |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022001434A true MX2022001434A (es) | 2022-02-22 |
Family
ID=74503032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001434A MX2022001434A (es) | 2019-08-05 | 2020-08-04 | Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220283167A1 (es) |
EP (1) | EP4011391A4 (es) |
JP (1) | JPWO2021025031A1 (es) |
KR (1) | KR20220041099A (es) |
CN (1) | CN114206386A (es) |
AU (1) | AU2020327251A1 (es) |
BR (1) | BR112022002098A2 (es) |
CA (1) | CA3149537A1 (es) |
IL (1) | IL290266A (es) |
MX (1) | MX2022001434A (es) |
TW (1) | TW202120692A (es) |
WO (1) | WO2021025031A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116113435A (zh) * | 2020-09-08 | 2023-05-12 | 学校法人埼玉医科大学 | 用于预测对癌症治疗的响应的生物标志物 |
KR20220158613A (ko) | 2021-05-24 | 2022-12-01 | 영남대학교 산학협력단 | 메티오닌을 유효성분으로 함유하는 병용투여를 위한 면역항암용 약학조성물 |
US20230025464A1 (en) * | 2021-07-09 | 2023-01-26 | Macrogenics, Inc. | Pharmaceutical compositions of a pd-1 antibody and use of the same |
CN117281902A (zh) * | 2023-11-23 | 2023-12-26 | 广州誉衡生物科技有限公司 | 一种药物组合物在制备治疗黑色素瘤产品中的应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE555319A (es) | 1956-03-21 | 1900-01-01 | ||
US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
JP4488125B2 (ja) | 1999-06-30 | 2010-06-23 | ライオン株式会社 | 毛髪用組成物 |
CN101213297B (zh) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
CA2923184A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
JP6405457B2 (ja) | 2014-09-11 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Pd−1/pd−l1およびcd80(b7−1)/pd−l1タンパク質/タンパク質相互作用の大環状阻害剤 |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
TW201726623A (zh) | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
MX2018007774A (es) | 2015-12-22 | 2018-11-09 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
CN109153670B (zh) | 2016-05-23 | 2022-03-15 | 中国医学科学院药物研究所 | 烟醇醚类衍生物、及其制法和药物组合物与用途 |
ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
KR20210018253A (ko) * | 2018-05-31 | 2021-02-17 | 오노 야꾸힝 고교 가부시키가이샤 | 면역 체크포인트 저해약의 유효성 판정 바이오마커 |
-
2020
- 2020-08-04 TW TW109126354A patent/TW202120692A/zh unknown
- 2020-08-04 CA CA3149537A patent/CA3149537A1/en active Pending
- 2020-08-04 MX MX2022001434A patent/MX2022001434A/es unknown
- 2020-08-04 AU AU2020327251A patent/AU2020327251A1/en active Pending
- 2020-08-04 CN CN202080055632.1A patent/CN114206386A/zh active Pending
- 2020-08-04 WO PCT/JP2020/029882 patent/WO2021025031A1/ja active Application Filing
- 2020-08-04 JP JP2021537327A patent/JPWO2021025031A1/ja active Pending
- 2020-08-04 EP EP20849435.1A patent/EP4011391A4/en active Pending
- 2020-08-04 US US17/632,423 patent/US20220283167A1/en active Pending
- 2020-08-04 BR BR112022002098A patent/BR112022002098A2/pt not_active Application Discontinuation
- 2020-08-04 KR KR1020227003427A patent/KR20220041099A/ko unknown
-
2022
- 2022-01-31 IL IL290266A patent/IL290266A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JPWO2021025031A1 (es) | 2021-02-11 |
KR20220041099A (ko) | 2022-03-31 |
WO2021025031A1 (ja) | 2021-02-11 |
US20220283167A1 (en) | 2022-09-08 |
IL290266A (en) | 2022-04-01 |
CA3149537A1 (en) | 2021-02-11 |
BR112022002098A2 (pt) | 2022-04-12 |
TW202120692A (zh) | 2021-06-01 |
EP4011391A4 (en) | 2023-08-16 |
CN114206386A (zh) | 2022-03-18 |
EP4011391A1 (en) | 2022-06-15 |
AU2020327251A1 (en) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001434A (es) | Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios. | |
MX2023006766A (es) | Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer. | |
EA201992220A1 (ru) | Комбинированная терапия для лечения или предупреждения опухолей | |
PH12017502391A1 (en) | Compositions and methods for inhibiting arginase activity | |
EP4085919A3 (en) | Compositions and methods to treat cancer | |
PH12020552011A1 (en) | Biomarkers for determining the effectiveness of immune checkpoint inhibitors | |
WO2017100362A3 (en) | Inhibitors of ezh2 and methods of use thereof | |
MX2018006781A (es) | Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap. | |
EA201692483A1 (ru) | Ингибиторы гистоновой метилазы | |
MX2020011684A (es) | Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer. | |
BR112015025944A8 (pt) | composição compreendendo inibidores do caminho do hedgehog e uso dos referidos inibidores | |
MX2017003464A (es) | Inhibidores de histona desmetilasa. | |
NZ738389A (en) | Inhibitor of igfbp3/tmem219 axis and diabetes | |
AR119934A1 (es) | Inhibidores de pikfyve para terapia contra el cáncer | |
MX2023011608A (es) | Metodos para inhibir ras. | |
WO2017214373A8 (en) | Diagnostic and therapeutic methods for cancer | |
MX2023002256A (es) | Inhibidores de sarm1. | |
JOP20220167A1 (ar) | مثبطات sarm1 | |
IL291424A (en) | Use of dkk-1 inhibitors to treat cancer | |
MX2022000783A (es) | Inhibidores de la ferroportina para el uso en la prevencion y el tratamiento de lesiones renales. | |
PH12019501918A1 (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
WO2019051025A3 (en) | Treatment for aggressive cancers by targeting c9orf72 | |
MX2019005194A (es) | Combinaciones de inhibidores de fgfr4 y secuestrantes de acido biliar. | |
MX2022003013A (es) | Tratamiento de enfermedades neurologicas con inhibidores del complemento. | |
EA202090304A1 (ru) | ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ |